CoChat

Fibrotic microtissue array to predict anti-fibrosis drug efficacy

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Fibrosis is a severe health problem characterized by progressive stiffening of tissues which causes organ malfunction and failure. A major bottleneck in developing new anti-fibrosis therapies is the lack of in vitro models that recapitulate dynamic changes in tissue mechanics during fibrogenesis. Here we create membranous human lung microtissues to model key biomechanical events occurred during lung fibrogenesis including progressive stiffening and contraction of alveolar tissue, decline in alveolar tissue compliance and traction force-induced bronchial dilation. With these capabilities, we provide proof of principle for using this fibrotic tissue array for multi-parameter, phenotypic analysis of the therapeutic efficacy of two anti-fibrosis drugs recently approved by the FDA. Preventative treatments with Pirfenidone and Nintedanib reduce tissue contractility and prevent tissue stiffening and decline in tissue compliance. In a therapeutic treatment regimen, both drugs restore tissue compliance. These results highlight the pathophysiologically relevant modeling capability of our novel fibrotic microtissue system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04336-z

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Development of arrays of membranous lung microtissues. a The lung alveolar sac wall features large surface area and small tissue thickness, which is characterized by the high span length (S) to thickness (t) ratio. b Engineered lung microtissues were developed to model the membranous morphology of the alveolar sac wall. c Finite element (FE) models were developed to study the effects of microtissue geometry and size on the evolution of contractile stress during microtissue formation. First principal stress contour was plotted on deformed microtissue geometry with overlaid plot of stress vectors, where applicable. Scale bar is 500 µm. Representative 2D-projected fluorescent confocal images of an experimentally-created four-leaflet lung microtissue stained for nucleus (d) and F-actin (e). Note highlighted area shows highly aligned F-actin stress fibers running along the diagonal axis of the microtissue, matching with the direction of the principal stress in highlighted area in c. Scale bar in d is 500 µm. f 3D isometric view of the same microtissue stained for collagen type-I. g Merged fluorescent cross-sectional view (F-actin and collagen type-I) taken at a′–a′ plane of the four-leaflet microtissue showing S/t ratio of 28, corresponding well to alveolar sac geometry. SEM images of a four leaflet (h) and a three leaflet (i) human lung fibroblast-populated microtissue. j Arrays of square lung microtissues were integrated into a 12-well plate to enable parallel testing of multiple pharmacological conditions. Bright spots in each well correspond to individual microtissues. k Immunofluorescence imaging of the microtissue array allowed multi-parameter, phenotypic analysis of the drug efficacy. Scale bar is 3 mm
Fig. 1 Development of arrays of membranous lung microtissues. a The lung alveolar sac wall features large surface area and small tissue thickness, which is characterized by the high span length (S) to thickness (t) ratio. b Engineered lung microtissues were developed to model the membranous morphology of the alveolar sac wall. c Finite element (FE) models were developed to study the effects of microtissue geometry and size on the evolution of contractile stress during microtissue formation. First principal stress contour was plotted on deformed microtissue geometry with overlaid plot of stress vectors, where applicable. Scale bar is 500 µm. Representative 2D-projected fluorescent confocal images of an experimentally-created four-leaflet lung microtissue stained for nucleus (d) and F-actin (e). Note highlighted area shows highly aligned F-actin stress fibers running along the diagonal axis of the microtissue, matching with the direction of the principal stress in highlighted area in c. Scale bar in d is 500 µm. f 3D isometric view of the same microtissue stained for collagen type-I. g Merged fluorescent cross-sectional view (F-actin and collagen type-I) taken at a′–a′ plane of the four-leaflet microtissue showing S/t ratio of 28, corresponding well to alveolar sac geometry. SEM images of a four leaflet (h) and a three leaflet (i) human lung fibroblast-populated microtissue. j Arrays of square lung microtissues were integrated into a 12-well plate to enable parallel testing of multiple pharmacological conditions. Bright spots in each well correspond to individual microtissues. k Immunofluorescence imaging of the microtissue array allowed multi-parameter, phenotypic analysis of the drug efficacy. Scale bar is 3 mmCC BY · PubMed Central
Fig. 2 Recapitulation of tissue fibrogenesis in lung microtissues. a Overview of the strategy for fibrosis induction and evaluation based on the measurements of biomarker expression and tissue contractile force. b Continuous TGF-β1 treatment induced strong expressions of α-SMA stress fibers, cytosolic pro-collagen, and EDA-Fibronectin (Fn) in lung fibroblast-populated microtissue, as illustrated by representative fluorescent confocal images. c Fluorescence intensity levels of α-SMA, pro-collagen, and EDA-Fibronectin in TGF-β1-treated and untreated microtissues. d SEM images of an untreated and a TGF- β1-treated microtissue. Significant micropillar deflection caused by elevated tissue contraction can be seen in TGF- β1-treated microtissue. e Time-lapsed microtissue contractile force measurement. Contractile force of TGF-β1-treated samples nearly doubled that of untreated samples at every time point over a 6 day period. Data are reported as the mean ± SD. n ≥ 10; *P < 0.001 when compared to untreated condition by one-way ANOVA with Tukey test. Scale bar is 200 µm
Fig. 2 Recapitulation of tissue fibrogenesis in lung microtissues. a Overview of the strategy for fibrosis induction and evaluation based on the measurements of biomarker expression and tissue contractile force. b Continuous TGF-β1 treatment induced strong expressions of α-SMA stress fibers, cytosolic pro-collagen, and EDA-Fibronectin (Fn) in lung fibroblast-populated microtissue, as illustrated by representative fluorescent confocal images. c Fluorescence intensity levels of α-SMA, pro-collagen, and EDA-Fibronectin in TGF-β1-treated and untreated microtissues. d SEM images of an untreated and a TGF- β1-treated microtissue. Significant micropillar deflection caused by elevated tissue contraction can be seen in TGF- β1-treated microtissue. e Time-lapsed microtissue contractile force measurement. Contractile force of TGF-β1-treated samples nearly doubled that of untreated samples at every time point over a 6 day period. Data are reported as the mean ± SD. n ≥ 10; *P < 0.001 when compared to untreated condition by one-way ANOVA with Tukey test. Scale bar is 200 µmCC BY · PubMed Central
Fig. 3 Modeling fibrotic tissue stiffening in lung microtissues. a Overview of the strategy for fibrosis induction and evaluation based on the measurement of tissue stiffness and compliance. b Mechanical stretching of the membranous microtissue mimics the respiratory distention of the alveolar sac walls. Top: unstretched microtissue array was bonded to a transparent stretchable substrate, which was mounted on a loading frame directly above microscope objective. Bottom: microtissue array under stretch. c Schematic shows the principle of tissue stiffness measurement. d Phase contrast images of microtissues before and under stretching. Stretch-induced extension of TGF-β1-treated microtissue (ΔL1 + ΔL2) was much less than that of untreated microtissue (ΔL1′ + ΔL2′), indicating reduced compliance for TGF-β1-treated samples. e Plot of microtissue compliance shows a substantial decline in the compliance in TGF-β1-treated microtissues as compared to untreated microtissues. f Plot of microtissue stiffness shows much higher stiffness developed in TGF-β1-treated microtissues as compared to untreated microtissues. Data are reported as the mean ± SD. n ≥ 10; *P < 0.001 when compared to untreated condition by one-way ANOVA with Tukey test. Scale bar is 200 µm
Fig. 3 Modeling fibrotic tissue stiffening in lung microtissues. a Overview of the strategy for fibrosis induction and evaluation based on the measurement of tissue stiffness and compliance. b Mechanical stretching of the membranous microtissue mimics the respiratory distention of the alveolar sac walls. Top: unstretched microtissue array was bonded to a transparent stretchable substrate, which was mounted on a loading frame directly above microscope objective. Bottom: microtissue array under stretch. c Schematic shows the principle of tissue stiffness measurement. d Phase contrast images of microtissues before and under stretching. Stretch-induced extension of TGF-β1-treated microtissue (ΔL1 + ΔL2) was much less than that of untreated microtissue (ΔL1′ + ΔL2′), indicating reduced compliance for TGF-β1-treated samples. e Plot of microtissue compliance shows a substantial decline in the compliance in TGF-β1-treated microtissues as compared to untreated microtissues. f Plot of microtissue stiffness shows much higher stiffness developed in TGF-β1-treated microtissues as compared to untreated microtissues. Data are reported as the mean ± SD. n ≥ 10; *P < 0.001 when compared to untreated condition by one-way ANOVA with Tukey test. Scale bar is 200 µmCC BY · PubMed Central
Fig. 4 Modeling the biomechanics of traction bronchiectasis. a Schematic shows the formation of numerous cystic airspaces in the fibrotic lung interstitium due to traction force-induced bronchial dilation. b The bronchial dilation was modeled through inducing the dilation of tissue openings in engineered fibrotic microtissues. FE simulated first principal stress distribution of a square microtissue supported by flexible micropillars (c), a square microtissue supported by rigid micropillars (d) and a long microtissue supported by rigid micropillars (e). Note high stress concentration around the micropillars in d and e induced dilation of the tissue opening. f Overview of the strategy for fibrosis induction in long microtissue and fibrosis evaluation based on the measurement of stress concentration and tissue opening size. g Merged immunofluorescence images of α-SMA and collagen type-I of untreated and TGF-β1-treated long microtissues. Apparent dilation of openings around micropillars and in the belly region can be observed in TGF-β1-treated condition. Scale bar is 500 µm. h Enlarged views of collagen type-I and α-SMA of highlighted region in g. α-SMA positive myofibroblasts aligned circumferentially around the dilated openings, matched well with the direction of simulated principal stress vectors (i). j Plot of the percentage of microtissue area occupied by the openings. The opening area of TGF-β1-treated sample is significantly larger than that of untreated sample at day 6. Data are reported as the mean ± SD. n ≥ 5; *P < 0.001 when compared to untreated condition by one-way ANOVA with Tukey test
Fig. 4 Modeling the biomechanics of traction bronchiectasis. a Schematic shows the formation of numerous cystic airspaces in the fibrotic lung interstitium due to traction force-induced bronchial dilation. b The bronchial dilation was modeled through inducing the dilation of tissue openings in engineered fibrotic microtissues. FE simulated first principal stress distribution of a square microtissue supported by flexible micropillars (c), a square microtissue supported by rigid micropillars (d) and a long microtissue supported by rigid micropillars (e). Note high stress concentration around the micropillars in d and e induced dilation of the tissue opening. f Overview of the strategy for fibrosis induction in long microtissue and fibrosis evaluation based on the measurement of stress concentration and tissue opening size. g Merged immunofluorescence images of α-SMA and collagen type-I of untreated and TGF-β1-treated long microtissues. Apparent dilation of openings around micropillars and in the belly region can be observed in TGF-β1-treated condition. Scale bar is 500 µm. h Enlarged views of collagen type-I and α-SMA of highlighted region in g. α-SMA positive myofibroblasts aligned circumferentially around the dilated openings, matched well with the direction of simulated principal stress vectors (i). j Plot of the percentage of microtissue area occupied by the openings. The opening area of TGF-β1-treated sample is significantly larger than that of untreated sample at day 6. Data are reported as the mean ± SD. n ≥ 5; *P < 0.001 when compared to untreated condition by one-way ANOVA with Tukey testCC BY · PubMed Central
Fig. 5 Anti-fibrosis drug efficacy under preventative treatment. a Overview of the strategy for preventative anti-fibrosis treatment and evaluation of the anti-fibrosis efficacy based on the measurement of biomarker expression and tissue mechanical properties. Pirfenidone (Pirf.) and Nintedanib (Nint.) were co-administered with TGF-β1 at the beginning of experiments and remained throughout the 6 day treatment period. b Representative immunofluorescence images of nuclei, α-SMA and pro-collagen of microtissues at day 6, with or without preventative anti-fibrosis treatments. Scale bar is 200 µm. c Plot of tissue-level fluorescence intensity of α-SMA and pro-collagen at day 6. d Time-lapsed measurement of microtissue contractile force. e Representative fluorescent images of collagen type-I of TGF- β1-treated and Pirf.-treated long microtissues. Zoom-in views showed that dilation of opening was inhibited by Pirf. treatment. Scale bar is 500 µm. f Time-lapsed plot of the percentage microtissue area occupied by the tissue openings. Pirfenidone treatment almost completely inhibited opening dilation at day 6. g Plot of the microtissue stiffness measured by tensile test at day 6. h Plot of the microtissue compliance measured at day 6. Data are reported as the mean ± SD. n ≥ 10; *P < 0.05 when compared to TGF-β1-treated condition; **P < 0.001 when compared to TGF-β1-treated condition. Statistical significance was determined by one-way ANOVA with Tukey test
Fig. 5 Anti-fibrosis drug efficacy under preventative treatment. a Overview of the strategy for preventative anti-fibrosis treatment and evaluation of the anti-fibrosis efficacy based on the measurement of biomarker expression and tissue mechanical properties. Pirfenidone (Pirf.) and Nintedanib (Nint.) were co-administered with TGF-β1 at the beginning of experiments and remained throughout the 6 day treatment period. b Representative immunofluorescence images of nuclei, α-SMA and pro-collagen of microtissues at day 6, with or without preventative anti-fibrosis treatments. Scale bar is 200 µm. c Plot of tissue-level fluorescence intensity of α-SMA and pro-collagen at day 6. d Time-lapsed measurement of microtissue contractile force. e Representative fluorescent images of collagen type-I of TGF- β1-treated and Pirf.-treated long microtissues. Zoom-in views showed that dilation of opening was inhibited by Pirf. treatment. Scale bar is 500 µm. f Time-lapsed plot of the percentage microtissue area occupied by the tissue openings. Pirfenidone treatment almost completely inhibited opening dilation at day 6. g Plot of the microtissue stiffness measured by tensile test at day 6. h Plot of the microtissue compliance measured at day 6. Data are reported as the mean ± SD. n ≥ 10; *P < 0.05 when compared to TGF-β1-treated condition; **P < 0.001 when compared to TGF-β1-treated condition. Statistical significance was determined by one-way ANOVA with Tukey testCC BY · PubMed Central
Fig. 6 Anti-fibrosis drug efficacy under therapeutic treatment. a Overview of the strategy for therapeutic anti-fibrosis treatment and evaluation of the anti-fibrosis efficacy based on the measurement of biomarker expression and tissue mechanical properties. Initial fibrosis progression was induced using TGF-β1 in the first three days and anti-fibrosis treatments were applied from day 3 to 6 without the presence of TGF-β1. b Representative immunofluorescence images of nuclei, α-SMA and pro-collagen of microtissues at day 6, with or without therapeutic anti-fibrosis treatments. TGF-β1 +3/−3 represents 3 days of TGF-β1 treatment followed by 3 days of normal culture condition without TGF-β1. Scale bar is 200 µm. c Plot of tissue-level fluorescence intensity of α-SMA and pro-collagen at day 6. d Time-lapsed measurement of microtissue contractile force. e Plot of microtissue stiffness measured by tensile test at day 6. f Plot of microtissue compliance measured at day 6. Data are reported as the mean ± SD. n ≥ 10; *P < 0.05 when compared to TGF-β1-treated condition. Statistical significance was determined by one-way ANOVA with Tukey test
Fig. 6 Anti-fibrosis drug efficacy under therapeutic treatment. a Overview of the strategy for therapeutic anti-fibrosis treatment and evaluation of the anti-fibrosis efficacy based on the measurement of biomarker expression and tissue mechanical properties. Initial fibrosis progression was induced using TGF-β1 in the first three days and anti-fibrosis treatments were applied from day 3 to 6 without the presence of TGF-β1. b Representative immunofluorescence images of nuclei, α-SMA and pro-collagen of microtissues at day 6, with or without therapeutic anti-fibrosis treatments. TGF-β1 +3/−3 represents 3 days of TGF-β1 treatment followed by 3 days of normal culture condition without TGF-β1. Scale bar is 200 µm. c Plot of tissue-level fluorescence intensity of α-SMA and pro-collagen at day 6. d Time-lapsed measurement of microtissue contractile force. e Plot of microtissue stiffness measured by tensile test at day 6. f Plot of microtissue compliance measured at day 6. Data are reported as the mean ± SD. n ≥ 10; *P < 0.05 when compared to TGF-β1-treated condition. Statistical significance was determined by one-way ANOVA with Tukey testCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. Wollin, L., Schuett, J. & Ostermann, A. The effect of nintedanib compared to pirfenidone on serum-stimulated proliferation of human primary lung fibroblasts at clinically relevant concentrations. Am. J. Respir. Crit. Care Med. 191, A4940 (2015).

Cited by

See all 154

Metadata

Authors
Asmani, M., Velumani, S., Li, Y., Wawrzyniak, N., Hsia, I., Chen, Z., Hinz, B., & Zhao, R.
Affiliations
  • University at Buffalo, State University of New York (US)
  • University of Toronto (CA)
Corresponding author
Zhao, Ruogang
Venue
Nature Communications
Published
2018-05-25
Volume
9
Issue
1
Pages
2066-2066
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2804064570
Cited by
137
References
47
Citations by year
2026: 9 · 2025: 16 · 2024: 11 · 2023: 21 · 2022: 17 · 2021: 25 · 2020: 19 · 2019: 18 · 2018: 1
FWCI
11.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health
  • University at Buffalo
  • National Institute of Biomedical Imaging and Bioengineering (R01EB019411)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
Keywords
pulmonary fibrosis, lung fibrogenesis, tissue stiffness, tissue contractility, pirfenidone, nintedanib, drug efficacy prediction, in vitro tissue models, tissue mechanics
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Cells, Cultured, Drug Evaluation, Preclinical, Fibroblasts, Fibrosis, Humans, Indoles, Lung, Lung Compliance, Pulmonary Fibrosis, Pyridones, Treatment Outcome, Tissue Culture Techniques, Tissue Scaffolds, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibrotic microtissue array to predict anti-fibrosis drug efficacy. https://app.cochat.ai/papers/10.1038/s41467-018-04336-z
The paper
Asmani, M., Velumani, S., Li, Y., Wawrzyniak, N., Hsia, I., Chen, Z., Hinz, B., & Zhao, R. (2018). Fibrotic microtissue array to predict anti-fibrosis drug efficacy. Nature Communications. https://doi.org/10.1038/s41467-018-04336-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.